Salvage Therapy with Ritonavir-Boosted Amprenavir/Fosamprenavir: Virological and Immunological Response in Two Years Follow-up

REFERENCES

• Pallela FJ Jr, Delaney MK, Moorman AC, et al. Declining morbidity and mortality among patients with advanced hu-man immunodeficiency virus infection. Outpatients Study Investigators. New Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Vella S, Benfield T, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 1998;352:1725–1730.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, March 23, 2004. Available at: http://www.AIDSinfo.nih.gov. Accessed September 4, 2004.
   Google Scholar
• Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for HIV infection. 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251–265.
   PubMed Web of Science ®Google Scholar
• Garcia L, Heneine W. Resistance of HIV-1 to reverse tran-scriptase and protease inhibitors: genotypic testing. J Clin ViroL 2001:197–212.
   PubMed Web of Science ®Google Scholar
• Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet. 2003;362: 2002–2011.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmaco enhancement. HIV Med. 2001;2:105–113.
   PubMedGoogle Scholar
• Sadler BM, Piliero PJ, Preston SL, Lloyd PP, Lou Y, Stein DS. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS. 200115: 1009–1018.
   Google Scholar
• Goujard C, Vincent I, Meynard JL, et al. Steady-state phar-macokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 2003;47:118–123.
   PubMed Web of Science ®Google Scholar
• Wood R, Arasteh K, Stellbrink HJ, et al. Six-week random-ized contolled trial to compare the tolerabilities, pharmaco-kinetics and antiviral activities of GW433908 and amprenavir in human-immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 2004;48:116–123.
   PubMed Web of Science ®Google Scholar
• Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. New Engl J Med. 2002;346:2039–2046.
   PubMed Web of Science ®Google Scholar
• Kemper CA, Wit MD, Keiser PH, et al. Sequencing of pro-tease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS. 200115: 609–615.
   Google Scholar
• Arvieux C, Tattevin P, Souala FM. et al. Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients. HIV Clin Trials. 2002;3:125–132.
   PubMedGoogle Scholar
• Bogner JR, Eberle J, Trendle U, Goebel D. Amprenavir in pre-treated patients: virological and immunological re-sponse in a cohort of 45 patients. Eur J Med Res. 2003; 8:49–55.
   PubMed Web of Science ®Google Scholar
• Clevenbergh P, Boulme R, Kirstetter M, Dellamonica P. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients. HIV Med. 2004:5;284–288.
   PubMed Web of Science ®Google Scholar
• Marcelin A, Lamotte C, Delaugerre C, et al. Genotypic inhibi-tory quotient as a predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2003;47:594–600.
   PubMed Web of Science ®Google Scholar
• Duval X, Lamotte C, Race E, et al. Amprenavir inhibitory quotient and virological response in human immunodefi-ciency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob Agents Chemother. 2002;46:570–574.
   PubMed Web of Science ®Google Scholar
• DeJesus E, LaMarca A, Sension M, Beltran C, Yéni P. The Context Study: efficacy and safety of GW433908/RTV in P1-experienced subjects with virological failure (24 week re-sults). In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston. Abstract 178.
   Google Scholar
• Genotypic testing algorithm of French ANRS AC11 guide-lines, 2003. Available at: http://www.hivfrenchresistance.org. Accessed September 2, 2004.
   Google Scholar
• Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulaions of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother. 2002;46:746–754.
   PubMed Web of Science ®Google Scholar
• Race R, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombination virus assay for patients failing on com-bination therapies. AIDS. 1999;13:2061–2068.
   PubMed Web of Science ®Google Scholar
• Tisdale M, Myers R, Randall S, et al. Resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies: a review. Clin Drug Invest. 2000;20:267–285.
   Web of Science ®Google Scholar
• Schmidt B, Korn K, Moschik B, et al. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors. Antimicrob Agents Chemother. 2000;44(11):3213–3216.
   PubMed Web of Science ®Google Scholar
• Paulsen D, Liao Q, Fusco G, StClair M, Shaefer M, Ross L. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. AIDS Res Hum Retroviruses. 2002;18:1011–1019.
   PubMed Web of Science ®Google Scholar
• Paulsen D, Elston R, Snowden W, Tisdale M, Ross L. Differ-entiation of genotype resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects. J Antimicrob Chemother. 2003;52:319–323.
   PubMed Web of Science ®Google Scholar
• Falcoz C, Jenkins JM, Bye C, et al. Pharmacokintics of GW433908, a prodrug of amprenavir, in healthy male volun-teers. J Clin PharmacoL 2002;42:887–898.
   PubMed Web of Science ®Google Scholar
• Pulido F, Katlama C, Marquez M, et al. A randomized study investigating the efficacy and safety of amprenavir in combi-nation with low-dose ritonavir in protease inhibitor-experi-enced HIV-infected adults. HIV Med. 2004:5;296–302.
   PubMed Web of Science ®Google Scholar
• The PLATO collaboration. Predictors of trend in CD4-posi-tive T-cell count and mortality among HIV-1-infected indi-viduals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51–62.
   PubMed Web of Science ®Google Scholar
• Raffanti S, Fusco J, D'Aquila R, et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr. 2004;37:1147–1154.
   PubMed Web of Science ®Google Scholar
• Pedneault L, Brothers C, Pagano G, Tymkewycz P, Yei J, Millard J, Fetter A. Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection. Clin Ther. 2000;22:1378–1394.
   PubMed Web of Science ®Google Scholar
• International AIDS Society Table, 2003. Available at: http://www.iasusa.org/resistancemutations/index.htlm. Ac-cessed September 2,2004.
   Google Scholar